Luminal diseases can lead to blockages in blood vessels or tubular structures in your body. Metallic and synthetic-covered stents are used to open these structures; however, your body may recognize the implants as foreign materials and respond with a negative reaction. This rejection leads to numerous complications including restenosis, inflammation, infection, allergic responses, scarring and thrombosis.
The AMStent™ is the first stent fully covered in amnion tissue, a proven biomaterial with regenerative properties. It has the promise to keep lumens open longer with potentially fewer complications than bare metal stents, covered stents or drug-eluting stents.
More than 100 years of clinical history with a growing list of applications
Favorable biologic properties and safety profile
Designed to restore and maintain long-term lumen patency
Thin, compliant amnion allows for stent delivery through a smaller catheter
The AMStent™ is fully covered in amnion tissue, which provides a bed for natural endothelialization to support the regeneration of healthy tissue
Complication/reintervention rates for current metallic tracheal stents range approximately 20-40%1-10
We recognize the source of our unique biomaterial and will always treat it with the utmost respect.
We strive to develop new products that improve patient quality of life, advance physicians' ability to treat luminal disease and lower healthcare system costs.
We are committed to being responsive to our customers and earning their trust every day.
We will hold ourselves to the highest standards of quality and integrity in everything we do.
We are accountable for delivering on our commitments and recognize that success requires a winning attitude, discipline, and a sense of urgency.
We will foster an environment for our talented team members to excel and contribute at the highest level.